on thursday, clorox and eli lilly talked to the analyst community. clorox has a decent story to tell based on new products and potential structure that would unlock value. lilly gave us a bad news about a cancer drug trial that didn't reached its targets. you know what, even here things are in washington's control. why? because they're both high-yielding stocks, 3.4% for clorox and 2.8% for eli lilly. and investors are still using higher-yielding stocks as bond market equivalents. they're hiding in these stocks to get good return, fixed income wise. now, these stocks are going to get hammered if we get a strong jobs report on friday. because interest rates will shoot past these stock yields as people fear the fed might take away the magic carpet ride. higher bond yields means lower lilly and clorox. here is the bottom line. one day we'll only have to talk about stocks and earnings and the game plan. this is not that day. stocks are simply dinghies. d-i-n-g-h-i-e-s. i'm from philadelphia so you probably don't understand it, but stocks are dinghies. be

. >> reporter: eli lilly is looking whether it may be more effective in early stage dementia patients while mirk is targeting an inhibit tore with mild symptoms. >> we probably won't see results from the studies for several more years. >> reporter: maybe a little hope says gloria purdy. >> i don't have hope s for the future, but it's a day at a time. it's not a pleasant day at a time. >> it's because i'm charming. >> and dick said it's because he's charming. >> bertha coombs, "nightly business report." >> and he is. >>> coming up, the roller costar economy but first a look at how commodities, currencies and treasuries faired today. >>> as summer draws to a close it's a season to remember for the major theme park companies. sales for nearly every one was sizzling hot. cedar fairs owns sandusky point in ohio. it raised the full year guidance yesterday reporting strong results through labor day thanks to higher spending per customer. so it's no wonder that the stock has skyrocketed more than 30% so far this year and as jane wells tells us, they are not alone. >> reporter: the economy is

. >> two big guns in the race, eli lilly, though they failed with advanced dementia patients.th early stage patients. analysts are watching whether america's anti-amyloid enzyme treatment will succeed with early stage patients. both are still years away from coming to market, but success could pay off big. >> the full opportunity really translates then into tens of billions of dollars if these drugs are effective on improving cognitive decline. >> really the big issue, if you get a drug like that, this is a blockbuster that could see upwards of $20 billion in sales annually, melissa. what people are looking for is something like a statin that will help keep that plaque from building up in the brain. >> bertha, thank you very much for that. dr. j, is this an investable thesis at this point? >> sure it is, but these are not binary bets because most of the binary bets because most of the companies, especially the ones you just identified, are doing multiple things. they're not just in one space. by that i mean they've got other revenue paths in case this doesn't work out. lily is

eli lilly falling after its experimental breast cancer drug failed late-stage trial.not submit it to the fda for approval. the sfok is down better than 3%. mccormick falling as well after lowering its guidance. the company known for its various spices is down 2 2/3%. ty? >>> the power house, we're going to travel to a top real estate market in america today. guess where that is. beautiful portland, oregon. find out how much house your money buys in the city of roses. >>> plus, after his spectacular america's cup win, oracle ceo larry ellison's multimillion-dollar paycheck getting some investors angry. we will explain. americans take care of business. they always have. they always will. that's why you take charge of your future. your retirement. ♪ ameriprise advisors can help you like they've helped millions of others. listening, planning, working one on one. to help you retire your way... with confidence. that's what ameriprise financial does. that's what they can do with you. ameriprise financial. more within reach. >>> welcome back to "power lunch." i'm diana olick.

a name you know, eli lilly, its experimental cancer drug fails in a breast cancer drug, but appears to somewhat with gastric cancer. the stock is down 2% on that. i've got carl icahn, you know, he said that apple stock is cheap. you know, we hear he's going to meet one-on-one, face-to-face with tim cook probably in new york next week. liz, what do you make of that? >> i think that carl icahn, he tweeted out a couple months ago he owns a large stake, not a large, quite a bit. he said, quote, quite a bit of apple shares and he wants a bigger stock buyback a than the one apple has right nnw. listen, without the big cash position, they're valued around 300 billion and not the 441 billion. he could be buying that stake as he's done with other companies to push it to do a bigger stock buyback or more dividends, right? >> if you've got 100 billion in cash, actually way more than that now days and maybe icahn will push for a dividend, but more of a stock buyback. something like that. >> yeah, he wants something, he wants something and he's in a position to meet with tim cook and get it, maybe.

and turn it around with some down arrows, names that are under pressure, and let's start off with eli lillyoving into the late stage of trials. these the first of cancer. and her down 1414%. at the airport they are not rending as many vehicles. volumes were low at the airport so that is to the downside and mccormick after their quarterly report down 2.5%. cheryl: thank you so much. they ensure everything from ships to the voice of bruce springsteen to the tune of $6 million. lloyd's of london is out with midyear earnings and i spoke with john nelson and asked him why profits were lower for the first half of this year. >> the first half, the business is in, the high risk end of specialist insurance. we had a relatively benign first task and very few catastrophe claims. underwriting profits were up 26%. that was counterbalanced by the investment returns being significantly down. the return in the first six months from 1.2% to 1.5%, that was caused by market conditions. in general, the late's market where we hold assets to pay claims and they have to be cash, credit, relatively short corporate

that is eli lilly. tough news pertaining to breast cancer.en trying out they had disappointing results from the study. now they will only use the drug for stomach cancer exclusively as opposed to breast cancer. we saw the stock dropped though it recovered some of the earlier losses we saw in the day. back to you. ashley: nicole, thanks very much. tracy: which go over to sandra now because she is watching the bond market yields edging higher today. of course thanks to the fed's no taper. but they actually pulled back from the recent highs. right, sandra? >> yaw but the bond market is interesting one right now. we saw the 10-year yield peak above 3% leading up to the fed's announcement last wednesday. we have been in serious decline. had in fact we're on pace for the, bond prices to be up 11 out of the past 12 trading days. that is pushing the yield on the 10-year lower for 11 out of the past 12 trading days. right now the yield on the 10-year is at 2.65%. hsbc's global strategist came out with a note and said, that's nothing. they're predictin

the second is take a look at what eli lilly said today. they're having poor results with one of their breast cancer treatments. who has good results? you're talking about a celldex. it's just incredible. you see these companies that are doing targeted work against cancer. they are the dominant companies in terps of who is responsible for this rally. dominant. and they keep coming public -- >> you got a company come public yesterday that's part of that on the diagnostic side. >> yes. you look at celgene. one of the three-legged stools is breast cancer. they've given away a loft of th up side for breast cancer drugs. it is biotech leading this. my friends who are in biotech are saying listen, be careful, some of these companies are public now, they are basically research labs. they won't deliver anything for five, seven years and they're not going to have enough money. then again, if you think the economy is slowing, who has the greatest growth year over year? a company who discovers a new drug. very exciting group. >> facebook does look to